Novo blamed US pricing erosion and patent expiries in several markets for the bleak 2026 outlook.
Eyes are firmly on the drugmaker’s future revenue streams amid Keytruda’s looming patent expiry.
As 2025 results reveal a mixed year for Pfizer, the company is looking to turn its fortunes around with newly acquired Metsera's obesity assets.
With a budget of up to $20m, the collaboration will establish scalable, rapid manufacturing for recombinant-protein vaccines.
The BTD for zovegalisib is supported by data from the Phase I/II ReDiscover trial.
The deal provides SanegeneBio with an upfront payment of $200m.
